Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CureVac N.V (CVAC) EBITDA: 2018-2024

Historic EBITDA for CureVac N.V (CVAC) over the last 7 years, with Dec 2024 value amounting to $189.9 million.

  • CureVac N.V's EBITDA fell 119.59% to -$345,248 in Q2 2025 from the same period last year, while for Jun 2025 it was -$55.2 million, marking a year-over-year increase of 28.36%. This contributed to the annual value of $189.9 million for FY2024, which is 164.36% up from last year.
  • Per CureVac N.V's latest filing, its EBITDA stood at $189.9 million for FY2024, which was up 164.36% from -$295.0 million recorded in FY2023.
  • In the past 5 years, CureVac N.V's EBITDA registered a high of $189.9 million during FY2024, and its lowest value of -$471.6 million during FY2021.
  • For the 3-year period, CureVac N.V's EBITDA averaged around -$119.9 million, with its median value being -$254.5 million (2022).
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 260.20% in 2021, then skyrocketed by 164.36% in 2024.
  • Over the past 5 years, CureVac N.V's EBITDA (Yearly) stood at -$130.9 million in 2020, then crashed by 260.20% to -$471.6 million in 2021, then skyrocketed by 46.04% to -$254.5 million in 2022, then declined by 15.92% to -$295.0 million in 2023, then spiked by 164.36% to $189.9 million in 2024.